Gam Holding Ag Cerevel Therapeutics Holdings, Inc. Transaction History

Gam Holding Ag

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 26, 2024	SELL	$38.96 - $42.75 $38,960 - $42,750	-1,000 Reduced 16.67%	5,000 $204,000
Q1 2024 May 13, 2024	BUY	$40.88 - $43.27 $40,880 - $43,270	1,000 Added 20.0%	6,000 $253,000
Q4 2023 Jan 23, 2024	BUY	$20.27 - $42.44 $101,350 - $212,200	5,000 New	5,000 $212,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Gam Holding Ag, based on Form 13F filings with the SEC.

Stay updated on Gam Holding Ag with notifications on news.